Nomura Increases GALAPAGOS NV/S (NASDAQ:GLPG) Price Target to $209.00

GALAPAGOS NV/S (NASDAQ:GLPG) had its price target lifted by Nomura from $140.00 to $209.00 in a research note released on Monday, The Fly reports. They currently have a buy rating on the biotechnology company’s stock.

GLPG has been the subject of several other reports. Morgan Stanley lifted their price objective on shares of GALAPAGOS NV/S from $138.00 to $139.00 and gave the stock an overweight rating in a research note on Monday, April 29th. Credit Suisse Group reaffirmed an outperform rating on shares of GALAPAGOS NV/S in a research note on Wednesday, July 10th. Stifel Nicolaus lifted their price objective on shares of GALAPAGOS NV/S from $121.00 to $188.00 and gave the stock a buy rating in a research note on Monday, July 15th. ValuEngine raised shares of GALAPAGOS NV/S from a buy rating to a strong-buy rating in a research note on Thursday, April 4th. Finally, BidaskClub raised shares of GALAPAGOS NV/S from a buy rating to a strong-buy rating in a research note on Saturday, July 13th. Three analysts have rated the stock with a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company. The company currently has a consensus rating of Buy and a consensus price target of $156.45.

NASDAQ GLPG opened at $174.23 on Monday. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.40 and a quick ratio of 6.40. The stock’s fifty day moving average price is $148.13. The stock has a market capitalization of $9.06 billion, a price-to-earnings ratio of -263.98 and a beta of 1.54. GALAPAGOS NV/S has a 52 week low of $85.00 and a 52 week high of $191.63.

A number of institutional investors have recently made changes to their positions in the business. Sigma Planning Corp acquired a new position in shares of GALAPAGOS NV/S in the second quarter worth $212,000. Pinnacle Associates Ltd. acquired a new position in GALAPAGOS NV/S in the first quarter valued at $231,000. FDx Advisors Inc. increased its stake in GALAPAGOS NV/S by 5.6% in the second quarter. FDx Advisors Inc. now owns 2,154 shares of the biotechnology company’s stock valued at $278,000 after purchasing an additional 115 shares during the last quarter. Financial Gravity Wealth Inc. acquired a new position in GALAPAGOS NV/S in the first quarter valued at $344,000. Finally, Stevens Capital Management LP acquired a new position in GALAPAGOS NV/S in the first quarter valued at $398,000. Institutional investors and hedge funds own 17.04% of the company’s stock.

GALAPAGOS NV/S Company Profile

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.

See Also: How Do Mutual Funds Work?

The Fly

Analyst Recommendations for GALAPAGOS NV/S (NASDAQ:GLPG)

Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.